
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals has reported positive top-line results from a recent study, indicating additional potential for their radiopharmaceuticals in prostate cancer diagnosis, which could significantly enhance their U.S. revenue segment. In the second half of 2025, the company's precision medicine business generated $316 million, with sequential revenue growth driven by successful U.S. sales, reflecting strong execution and commercial performance. The potential approval of new agents for prostate cancer could expand the total addressable market by approximately $3.5 billion, further bolstering Telix's financial outlook.
Bears say
Telix Pharmaceuticals reported a net loss of $1.0 million, translating to an earnings per share (EPS) of $(0.30), which was worse than both internal estimates and consensus expectations. The company faces multiple risks that could negatively impact its future performance, including potential adverse clinical results for its lead asset TLX591, delays in advancing pipeline candidates, and challenges in obtaining timely regulatory approvals. Additionally, Telix is exposed to competitive pressures and long-term dilution risks, alongside balance sheet and liquidity concerns, which collectively contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares